Efficacy And Safety Of Dabigatran In The Senile Patients Nonvalvular Atrial Fibrillation

Objectives1.To observe effect of anticoagulant with dabigatran etexilate in sensile patients with non-valvular atrial fibrillation(NVAF).2.To observe the safety of anticoagulation with dabigatran etexilate in sensile patients with non-valvular atrial fibrillation.MethodsA total of 106 patients with non-valvular atrial fibrillation who were 65 years old or older and were admitted to the JingNing First People’s Hospital from May 2015 to May 2016 were collected,and take dabigatran etexilate capsules 110 mg twice daily for anticoagulation.A total of 50 patients aged 65-74 were divided into old groups.Fifty-six patients aged 75 and over were divided into senile groups,we recorded and improved the general conditions of age,sex,etc.of all patients.We measured the prothrombin time(PT)and activated partial thrombin time before taking the drug,taking 1 week,taking 1 month,and taking 1 year.(Activated part of clotting enzyme live time,APTT),Thrombin time(TT),D-dimer(DD),The international standard ratio(INR),Alanine transaminase(ALT),aspartate aminotransferase(AST),and serum creatinine(Scr)values were recorded.Bleeding events(intracranial hemorrhage,subcutaneous hemorrhage)were recorded in the two groups of patients after medication.,digestive system bleeding,urinary system bleeding,retinal hemorrhage,bleeding gums,etc.),ischemic stroke events,arterial thromboembolic events(limb artery embolization,mesenteric artery embolism,renal artery embolism,etc.)and various adverse reactions Number of cases.Results1.A paired t-test was performed on the PT,TT,and APTT at 1 week,1 month,and 1 year of taking dabigatran etexilate caPsules in the two groups of Patients and the PT,TT,and APTT values before taking the drug,respectively.Both increased compared with those before taking the drug,and the difference was statistically significant(P<0.05),but did not exceed the normal range.There was no significant difference in DD and INR before and after medication(P>0.05).2.The rate of ischemic stroke in two groups was determined by Fisher test(P=1.00>0.05),the difference was not statistically significant.3.There were no significant changes in ALT,AST,and Scr at 1 week,1 month,and 1year after taking dabigatran etexilate capsules in both groups(P>0.05).During the experimental period,liver and kidney function were damaged in each group after the two groups of subjects were taken,but there was no significant difference in liver and kidney function damage between the two groups(P>0.05).4.The rate of bleeding in both groups was determined by Fisher test P=0.75>0.05,and the difference was not statistically significant.5.No patients experienced arterial thromboembolism during the follow-up period.6.Both groups of patients experienced adverse reactions during the experiment,but the difference in adverse reaction rates between the two groups was not statistically significant(P>0.05).Conclusions1.The use of dabigatran eterate anticoagulation therapy is effective in elderly patients with non-valvular atrial fibrillation.2.The use of dabigatran eterate anticoagulation therapy is safety in elderly patients with non-valvular atrial fibrillation.